NCT04352361View on ClinicalTrials.gov

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

April 29, 2020

Study Completion Date

April 29, 2020

Conditions
Healthy
Interventions
DRUG

TVB-2640

TVB-2640 tablets (25mg/50mg/75mg) one tablet at a time, once per day.

DRUG

Placebo

Oral, matching number of placebo Tablets with active arm.

Trial Locations (1)

410002

Hunan provincial people's hospital, Changsha

Sponsors
All Listed Sponsors
lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY

NCT04352361 - Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects | Biotech Hunter | Biotech Hunter